NCT05151159View on ClinicalTrials.gov

Prognostic Value of Protein IMP3 Expression in Cervical Cancer

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2003

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2022

Conditions
Cervical Carcinoma
Interventions
OTHER

immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3

All Listed Sponsors
lead

University of Mostar

OTHER

NCT05151159 - Prognostic Value of Protein IMP3 Expression in Cervical Cancer | Biotech Hunter | Biotech Hunter